Search

Your search keyword '"Marco Ladetto"' showing total 10 results
Start Over Author "Marco Ladetto" Journal hemasphere
10 results on '"Marco Ladetto"'

1. S221: LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)

Author

Marco Ladetto, Rita Tavarozzi, Andrea Evangelista, Elisa Genuardi, Daniela Drandi, Michael Mian, Manuela Zanni, Federica Cavallo, Alice DI Rocco, Vittorio Stefoni, Chiara Pagani, Alessandro Re, Annalisa Chiappella, Monica Balzarotti, Vittorio Ruggero Zilioli, Maria Gomes Da Silva, Luca Arcaini, Annalia Molinari, Filippo Ballerini, Andrés José María Ferreri, Fabio Benedetti, Piero Maria Stefani, Benedetta Puccini, Caterina Stelitano, Elisa Bossi, Mario Luppi, Giovannino Ciccone, Umberto Vitolo, Maurizio Martelli, Simone Ferrero, and Sergio Cortelazzo

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

2. S231: PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY

Author

Annalisa Chiappella, Anna Dodero, Anna Guidetti, Silva Ljevar, Martina Pennisi, Beatrice Casadei, Eugenio Galli, Alice DI Rocco, Ilaria Cutini, Anna Maria Barbui, Stefania Bramanti, Maurizio Musso, Maria Chiara Tisi, Matteo Giovanni Carrabba, Massimo Martino, Mirko Farina, Barbara Botto, Giovanni Grillo, Marco Ladetto, Jacopo Olivieri, Luca Arcaini, Anisa Bermema, Rosalba Miceli, Patrizia Chiusolo, Pier Luigi Zinzani, and Paolo Corradini

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

3. P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE

Author

Annalisa Chiappella, Anna Dodero, Silva Ljevar, Martina Pennisi, Francesca Bonifazi, Chiara De Philippis, Eugenio Galli, Alice DI Rocco, Maria Chiara Tisi, Ilaria Cutini, Matteo Giovanni Carrabba, Maurizio Musso, Massimo Martino, Anna Maria Barbui, Barbara Botto, Mirko Farina, Giovanni Grillo, Francesca Patriarca, Marco Ladetto, Luca Arcaini, Anisa Bermema, Rosalba Miceli, Martina Magni, Maurizio Martelli, Patrizia Chiusolo, Stefania Bramanti, Pier Luigi Zinzani, Cristiana Carniti, and Paolo Corradini

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network

Author

Barbara Mantoan, Elisa Genuardi, Martina Ferrante, Irene Della Starza, Elena Ciabatti, Susanna Grassi, Lucia Anna De Novi, Marzia Cavalli, Claudia Mannu, Anna Gazzola, Riccardo Bomben, Massimo Degan, Beatrice Alessandria, Christiane Pott, Marie-Hélène Delfau-Larue, Ramon García-Sanz, Claudio Agostinelli, Valter Gattei, Sara Galimberti, Ilaria Del Giudice, Gianluca Gaidano, Marco Ladetto, Simone Ferrero, Daniela Drandi, and on behalf of the Fondazione Italiana Linfomi (FIL) MRD Network

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2021
Full Text
View/download PDF

6. Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network

Author

Daniela Drandi, Marion Alcantara, Ichrafe Benmaad, Arian Söhlbrandt, Ludovic Lhermitte, GianMaria Zaccaria, Martina Ferrante, Elisa Genuardi, Barbara Mantoan, Patrick Villarese, Morgane Cheminant, Irene della Starza, Elena Ciabatti, Riccardo Bomben, Cristina Jimenez, Mary Callanan, Chrystelle Abdo, Cornelia Eckert, Vincent Ribrag, Sergio Cortelazzo, Martin Dreyling, Olivier Hermine, Marie-Hélène Delfau-Larue, Christiane Pott, Marco Ladetto, Simone Ferrero, and Elizabeth Macintyre

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract. Minimal residual disease (MRD) has been increasingly investigated in mantle cell lymphoma (MCL), including for individual therapeutic stratification and pre-emptive treatment in clinical trials. Although patient/allele specific real-time quantitative polymerase chain reaction (qPCR) of IGH or BCL1-IGH clonal markers is the gold-standard method, its reliance on a standard curve for relative quantification limits quantification of low-level positivity within the 1E-4 to 1E-5 range; over half of positive MRD samples after treatment fall below the quantitative range (BQR) of the standard curve. Droplet digital PCR (ddPCR), in contrast, allows absolute quantification, including for samples with no baseline determination of tumor infiltration by multicolor flow cytometry (MFC), avoiding the need for a reference standard curve. Using updated, optimized, ddPCR criteria we compared it with qPCR in 416 MRD samples (and with MFC in 63), with over-representation (61%) of BQR results by qPCR, from a total of 166 patients from four prospective MCL clinical trials. ddPCR, qPCR and MFC gave comparable results in MRD samples with at least 0.01% (1E-4) positivity. ddPCR was preferable to qPCR since it provided more robust quantification at positivity between 1E-4 and 1E-5. Amongst 240 BQR samples with duplicate or triplicate analysis, 39% were positive by ddPCR, 49% negative and only 12% remained positive below quantifiable ddPCR limits. The prognostic relevance of ddPCR is currently under assessment in the context of prospective trials within the European MCL Network.

Published
2020
Full Text
View/download PDF

8. Controversies in the Treatment of Follicular Lymphoma

Author

Kai Hübel, Michele Ghielmini, Marco Ladetto, and Ajay K. Gopal

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract. The overall prognosis of patients with follicular lymphoma has substantially improved over the last decades with a 10-year overall survival of around 80% for the majority of patients. However, for most patients follicular lymphoma it is still a relapsing and remitting disease. Furthermore, certain subsets of patients still have much shorter survival. Currently, there is no established standard how to treat high-risk follicular lymphoma. With advances in the understanding of the biology and pathogenesis of B cell malignancies, a plethora of new compounds have been investigated in FL. These compounds have the potential to increase efficacy if added to current regimens or even replace them. The implementation of these compounds in treatment algorithms is another unsolved issue. This overview highlights major controversies in the treatment of follicular lymphoma and discusses the most recent and relevant clinical trials.

Published
2020
Full Text
View/download PDF

10. Droplet Digital PCR Assay for MYD88L265P: Clinical Applications in Waldenström Macroglobulinemia

Author

Irene Dogliotti, Mariella Lo Schirico, Davide Bertuzzo, Martina Ferrante, Simone Ferrero, Marco Ladetto, Giulia Benevolo, Paola Omedè, B. Ferrero, Daniela Drandi, Alberto Zamo, Mario Boccadoro, and Federica Cavallo

Subjects
Pathology, medicine.medical_specialty, lcsh:RC633-647.5, business.industry, Waldenstrom macroglobulinemia, Case Report, lcsh:Diseases of the blood and blood-forming organs, Hematology, medicine.disease, MYD88 L265P, Medicine, Digital polymerase chain reaction, business
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results